Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › non-alcoholic fatty liver disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD)

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for non-alcoholic fatty liver disease (NAFLD)

5 trials tracked for non-alcoholic fatty liver disease (NAFLD).

5Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 4 Other / NA 1
  1. Phase 2 A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects. Completed
  2. Phase 2 A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. Completed
  3. Phase 2 A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease. Completed
  4. Phase 2 Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients Completed
  5. N/A How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)? Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Circular RNAs regulate hepatic lipid metabolism in NAFLD and MASLD via key signaling pathways
Genetics & Precision Medicine Sys. Review
Circular RNAs regulate hepatic lipid metabolism in NAFLD and MASLD via key signaling pathways Circular RNAs May Offer New Paths for Fatty Liver Disease
This systematic review synthesizes evidence on circular RNAs (circRNAs) in non-alcoholic fatty liver disease (NAFLD) and metabolic dysfuncti…
New research explores how circular RNAs could serve as important tools for diagnosing and treating fatty liver diseases like NAFLD and MASLD…
Frontiers Jun 16, 2026